An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
- Resource Type
- Article
- Source
- In
Annals of Oncology February 2010 21(2):275-282 - Subject
- Language
- ISSN
- 0923-7534